{
    "nct_id": "NCT04805333",
    "official_title": "A Phase 1 Dose Escalation of ArtemiCoffee in Patients With Advanced Ovarian Cancer",
    "inclusion_criteria": "* Able to understand and willing to sign a written informed consent document.\n* Age ≥ 18 years.\n* Patients diagnosed with Stage II-IV ovarian cancer who have completed initial first-line therapy with carboplatin and paclitaxel and achieved a complete response.\n* Creatinine clearance ≥ 60 mL/min\n* Total bilirubin ≤ 1.5 x ULN, and AST and ALT ≤ 3.0 x ULN\n* GOG Performance Status ≤ 2.\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study visits, in the opinion of the treating physician.\n* Pregnant women are excluded from this study.\n* Concurrent use of strong inducers of CYP2A6, including phenobarbital and rifampin\n* Women with active gastric ulcers are excluded from this study.\n* Patients who are receiving concurrent maintenance therapy with a PARP inhibitor for a known hereditary recombinant deficiency (HRD) mutation. Bevacizumab maintenance therapy is allowed.\n* Concurrent use of nevirapine, ritonavir and strong UGT inhibitors or inducers.",
    "miscellaneous_criteria": ""
}